This morning, we are revisiting a play that has been periodically appearing on our Extended Watchlists since this summer. Following a July 15th alert, we would see KNDI dip as low as 4.41 (07/23). We continued to monitor the stock through to September, as it went on to hit a high of 9.20 (10/26), marking an increase of 109% in roughly three month’s time. However, our adventures with KNDI had only just begun.
By early November, it had settled back to a low of 6.15, and it hasn’t looked back since. Moderate gains gave way to full-on breakout mode on Friday as the stock rocketed to a high of 10.4784, marking a gain of 70% off of its most recent low, and a 138% rise from our original alert low of 4.41. This huge move came just a few days after the following announcement:
- Kandi Technologies Announces Its Subsidiary Zhejiang Kandi Electric Vehicles Co., Ltd. (the “JV Company”) Signed the Ownership Transfer Agreement With Shanghai Maple Guorun Automobile Co., Ltd. GlobeNewswire (Dec 24)
This is definitely a story that we will continue to follow in the New Year, as the company expects to increase its delivery of electric vehicles. CEO Hu Xiaoming recently stated: “In 2014, we expect our EV business may surpass our legacy go-cart business and become a major revenue generator for the company,”
More information : http://www.kandivehicle.com
Peregrine Pharmaceuticals, Inc. PPHM
PPHM is an old-time favorite of ours that we wanted to call attention to this morning, as the stock is undergoing some notable pre-market trading action. From lows (1.25) following our most recent alert on PPHM is gapping up significantly, currently trading in the high 1.40’s on a PR fresh out this morning. We’re very interested to see how far the current trend will carry, so keep an eye peeled on PPHM.
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
TUSTIN, CA, Dec 30, 2013 (Marketwired via COMTEX) — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States. SUNRISE is a pivotal Phase III clinical trial comparing the company’s investigational immunotherapy bavituximab plus the chemotherapy docetaxel against placebo plus the chemotherapy docetaxel in patients with second-line non-small cell lung cancer (NSCLC). This trial will enroll approximately 600patients from more than 100 medical centers worldwide. >> FULL PR
Extended Watchlist:
AMMX, PROW, BIOL, CYTR, AVL(Coming off double-bottom)